title: [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.
abstract: OBJECTIVE
  To determine whether the standardized uptake value (SUV) of [(18)F]fluorodeoxyglucose uptake by positron emission tomography could be a prognostic factor for non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  One hundred sixty-two patients with stage I to IIIb NSCLC were analyzed. Overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and local-regional control (LRC) were calculated by the Kaplan-Meier method and evaluated with the log-rank test. The prognostic significance was assessed by univariate and multivariate analyses.
  
  
  RESULTS
  There were 93 patients treated with surgery and 69 patients treated with radiotherapy. A cutoff of 5 for the SUV for the primary tumor showed the best discriminative value. The SUV for the primary tumor was a significant predictor of OS (P = .02) in both groups. Low SUVs (</= 5.0) showed significantly better DFS rates than those with high SUVs (> 5.0; surgery group, P = .02; radiotherapy group, P = .0005). Low SUVs (</= 5.0) indicated a significantly better DFS than those with high SUVs (> 5.0; stage I or II, P = .02; stage IIIa or IIIb, P = .004). However, using the same cutoff point of 5, the SUV for regional lymph nodes was not a significant indicator for DFS (P = .19), LRC (P = .97), or DMFS (P = .17). The multivariate analysis showed that the SUV for the primary tumor was a significant prognostic factor for OS (P = .03) and DFS (P = .001).
  
  
  CONCLUSIONS
  The SUV of the primary tumor was the strongest prognostic factor among the patients treated by curative surgery or radiotherapy.
authors.affiliation: Department of Radiation Oncology, Unit 97, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
authors.forename: Ryohei
authors.initials: R
authors.lastname: Sasaki
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Komaki
authors.forename: Homer
authors.initials: H
authors.lastname: Macapinlac
authors.forename: Jeremy
authors.initials: J
authors.lastname: Erasmus
authors.forename: Pamela
authors.initials: P
authors.lastname: Allen
authors.forename: Kenneth
authors.initials: K
authors.lastname: Forster
authors.forename: Joe B
authors.initials: JB
authors.lastname: Putnam
authors.forename: Roy S
authors.initials: RS
authors.lastname: Herbst
authors.forename: Cesar A
authors.initials: CA
authors.lastname: Moran
authors.forename: Donald A
authors.initials: DA
authors.lastname: Podoloff
authors.forename: Jack A
authors.initials: JA
authors.lastname: Roth
authors.forename: James D
authors.initials: JD
authors.lastname: Cox
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000378:metabolism; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000628:therapy; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D019788:Fluorodeoxyglucose F18